Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (October 2026)
18 slides from Pluri's investor presentation, October 2026
Slide 1: Where Technology Comes To Life
Where Technology Comes To Life Company presentation October 2026 NASDAQ: PLUR TASE: PLUR.TA 1
Slide 2: Forward Looking Statement
DISCLAIMER Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the
Slide 3: About Pluri
PLURI AT A GLANCE About Pluri Cell-based innovation - across modalities 20+ Years 200+ ~$9m Years of cell-processing Global patents Cash & Deposits experience (as of June 30, 2026) GMP ~1,000 Patients Leadership In-house commercial-scale Discovery to Phase III Seasoned leadership facility CMC approv
Slide 4: Pluri's Unique Platform
PLURI AT A GLANCE Pluri's Unique Platform Next-generation cell-based solutions at scale - across two billion-dollar verticals ONE PLATFORM. TWO VERTICALS. INFINITE OPPORTUNITIES. HUMAN HEALTH & LONGEVITY FOODTECH & BIO-FARMING Cell therapies + regenerative aesthetics Plant + animal cells at industri
Slide 5: Our 3D Bioreactor Platform
TECHNOLOGY Our 3D Bioreactor Platform A proprietary system that expands any cell type - human, plant and animal into industrial-scale volumes with full reproducibility. Reproducible GMP-Certified Scalable Closed-system process, Manufacturing From lab-scale to batch-to-batch recognized commercial con
Slide 6: Human Health & Longevity
—— pluri Human Health & Longevity Advancing longevity and regenerative medicine at the cellular level Pluri inc. | October 2026
Slide 7: Longevity - a Macroeconomic Necessity
HUMAN HEALTH & LONGEVITY Longevity - a Macroeconomic Necessity Pluri Inc. | October 2026 7
Slide 8: The Rise of Longevity Investment Capital
HUMAN HEALTH & LONGEVITY The Rise of Longevity Investment Capital Longevity is no longer just a market - it's a new axis of power SOVEREIGN WEALTH FUNDS FAMILY OFFICES & ULTRAWEALTHY Longevity investment as national strategy The most important class of longevity backer $11.2T 220% Increase in global
Slide 9: Longevity - the Human Impact
HUMAN HEALTH & LONGEVITY Longevity - the Human Impact Aging is a multi-system decline. Pluri's regenerative cell platform targets its root cause. 1 Neurodegenerative 2 Cardiovascular 3 Hematopoietic Decline Alzheimer's, Parkinson's, Heart failure, vascular Bone marrow failure, cognitive decline insu
Slide 10: Cell Therapy - the Clinical Impact
IN THE NEWS | APRIL 2026 Cell Therapy - the Clinical Impact "He should have used stem cells." Dr. Jesse Morse, Sports Medicine Physician THE CONNECTION On Luka Dončić's Grade 2 hamstring strain treatment, 2026 Pluri makes exactly the cells the doctor recommended. "Choosing PRP instead of stem cells
Slide 11: PLX Cell Therapy Platform: Human Health & Longevity
HUMAN HEALTH & LONGEVITY PLX Cell Therapy Platform: Human Health & Longevity Allogeneic, placental-based, off-the-shelf therapy with multi-indication clinical track record ~1,000 patients participated in clinical trials globally · 20,000+ treatments per single placenta Muscle & Pain Vascular & Bone
Slide 12: Regenerative Aesthetics Through Cell Science
HUMAN HEALTH & LONGEVITY Regenerative Aesthetics Through Cell Science Transforming decades of cell-science expertise into next-generation aesthetics MARKET OPPORTUNITY SCIENCE-DRIVEN INNOVATION >$200B Plant EVs · Placental Exosomes Rich in exosomes, cytokines, and growth factors - designed to rejuve
Slide 13: Commercialization Opportunities
GOING TO MARKET Commercialization Opportunities A Regulatory opening - met with science, technology & clinical evidence U.S. Stem Cell Bill Cellav Commercial Launch Authorizes use of cell therapies in orthopedics, wound care U.S - Completed two regenerative aesthetic products listing. and pain manag
Slide 14: Cells are the Building Blocks of Life
OUR VISION Cells are the Building Blocks of Life. Aging and Health Climate Change Food Security Sustainability Our technologies enables scalable, sustainable solutions for a growing, aging world. Eight Billion Lives. One Planet. Zero Time to Waste. Pluri Inc. | October 2026 14
Slide 15: Innovating the Future of Food & Bio-Farming
FOODTECH & BIO-FARMING Innovating the Future of Food & Bio-Farming Pluri contributes its technology to each venture in exchange for majority ownership, scaling value across multiple verticals Cultivated Meat Cultivated Cacao 58% Pluri Ownership Current valuation $73.5M 79% Strategic JV Bühler partne
Slide 16: 2026 - Inflection Point
INFLECTION 2026 - Inflection Point Key catalysts converging across both verticals this year LONGEVITY & HEALTH WHY 2026 MATTERS A convergence year Cellav regulatory approvals across U.S. & EU & IL. Commercial launch of Cellav regenerative aesthetics products - • Transformational year: from R&D to co
Slide 17: Our Team
LEADERSHIP Our Team Seasoned leadership with proven track record in life-sciences and capital markets. Yaky Yanay Lior Raviv Liat Zalts CEO & PRESIDENT CHIEF TECHNOLOGY OFFICER CHIEF FINANCIAL OFFICER Efrat Kaduri Nimrod Bar Zvi Ori Shalem Nofar Glaich-Dabach CHIEF BUSINESS OFFICER CHIEF COMMERCIAL
Slide 18: Thank You
THANK YOU. FOR FURTHER INFORMATION investor.relations@pluri-biotech.com · www.pluri-biotech.com Matam Park, Building 5, Haifa 3508409, Israel · NASDAQ: PLUR · TASE: PLUR.TA 18